US-based X4 Pharmaceuticals has entered an exclusive agreement with United Arab Emirates (UAE)-based pharmaceutical products ...

X4 Pharmaceuticals announced the validation of its Marketing Authorization Application (MAA) for mavorixafor, a treatment for WHIM syndrome, by the European Medicines Agency (EMA). This rare ...

X4 Pharmaceuticals (XFOR) and taiba rare, a taiba Healthcare company with specialty & orphan drug marketing, sales, and distribution ...

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient ...

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025Right-sizing commercial efforts to ...

The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI®, an oral, once-daily ...

In recent transactions disclosed by X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), Chief Commercial Officer Mark Baldry has made significant stock acquisitions amid the company's current $85.6 million market ...

This acquisition was linked to the European Medicines Agency's acceptance of a Marketing Authorization Application for mavorixafor, a treatment for WHIM syndrome. Following these transactions ...

The focus on optimizing the U.S. promotion of XOLREMDI demonstrates the company's commitment to supporting the WHIM syndrome community and enhances potential market growth for the product.

The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI ®, an oral, once-daily ...